Autologous haematopoiesis stem cell transplantation (AHSCT) for treatment-refractory autoimmune diseases in children
Objectives To evaluate the long-term effectiveness and safety of autologous haematopoiesis stem cell transplantation (AHSCT) for severe, refractory autoimmune diseases in paediatric patients.Methods A single-centre study of consecutive children and adolescents with refractory autoimmune diseases und...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-07-01
|
| Series: | RMD Open |
| Online Access: | https://rmdopen.bmj.com/content/10/3/e004381.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832557483201134592 |
|---|---|
| author | Jasmin Beate Kuemmerle-Deschner Susanne Benseler Joerg C Henes Özlem Satirer Michaela Döring Till Lesk |
| author_facet | Jasmin Beate Kuemmerle-Deschner Susanne Benseler Joerg C Henes Özlem Satirer Michaela Döring Till Lesk |
| author_sort | Jasmin Beate Kuemmerle-Deschner |
| collection | DOAJ |
| description | Objectives To evaluate the long-term effectiveness and safety of autologous haematopoiesis stem cell transplantation (AHSCT) for severe, refractory autoimmune diseases in paediatric patients.Methods A single-centre study of consecutive children and adolescents with refractory autoimmune diseases undergoing AHSCT was performed. Demographics, clinical, laboratory features, pre-AHSCT medications, disease activity and functional status were captured. The primary outcome was progression-free survival, secondary outcomes included overall survival, disease-specific treatment responses, disease activity at the last follow-up and AHSCT safety.Results The study included seven patients: two systemic sclerosis, one pansclerotic morphoea, one eosinophilic fasciitis, one juvenile dermatomyositis and two patients with systemic juvenile idiopathic arthritis; four women, three men median age at AHSCT of 10 years (7–19), median follow-up post-AHSCT of 17 years. Median progression-free survival and overall survival was 4.2 years (95% CI: 0.98 to 8.3) and 17 years (95% CI: 11.8 to 22.1), respectively. Progression-free survival rates at 1 and 2 years post-AHSCT were 100% and 77%, respectively. All children survived. All patients are in clinical remission, only four require ongoing immunotherapy. Safety: Three experienced infections, including HHV6, Candida and Ralstonia sepsis; one developed a systemic inflammatory response syndrome; two new onset secondary autoimmune diseases including autoimmune haemolytic anaemia, Graves’ disease and one was found to have a breast fibroadenoma. Treatment toxicity: one cyclophosphamide-associated transient renal failure and pericardial effusion, one patient with amenorrhoea/infertility.Conclusions AHSCT was an effective and safe approach for children and adolescents with treatment-refractory autoimmune diseases. The indication and timing of transplantation requires a careful consideration and a multidisciplinary approach. |
| format | Article |
| id | doaj-art-e14c3860640944ca940a28071fe0e370 |
| institution | Kabale University |
| issn | 2056-5933 |
| language | English |
| publishDate | 2024-07-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | RMD Open |
| spelling | doaj-art-e14c3860640944ca940a28071fe0e3702025-02-03T04:35:19ZengBMJ Publishing GroupRMD Open2056-59332024-07-0110310.1136/rmdopen-2024-004381Autologous haematopoiesis stem cell transplantation (AHSCT) for treatment-refractory autoimmune diseases in childrenJasmin Beate Kuemmerle-Deschner0Susanne Benseler1Joerg C Henes2Özlem Satirer3Michaela Döring4Till Lesk5Department of Paediatrics and Autoinflammation reference Center Tuebingen (arcT), Universitatsklinikum Tubingen, Tubingen, Baden-Württemberg, GermanyRheumatology, Alberta Children`s Hospital Research Institute, Calgary, Alberta, CanadaCentre for Interdisciplinary Clinical Immunology, Rheumatology and Auto-inflammatory Diseases and Department of Internal Medicine II (Oncology, Haematology, Immunology and Rheumatology), Universitatsklinikum Tubingen, Tubingen, Baden-Württemberg, GermanyDepartment of Paediatrics and Autoinflammation reference Center Tuebingen (arcT), Universitatsklinikum Tubingen, Tubingen, Baden-Württemberg, GermanyPediatric Hematology &Oncology, University of Tübingen, Tubingen, Baden-Württemberg, GermanyUniversitatsklinikum Tubingen, Tubingen, Baden-Württemberg, GermanyObjectives To evaluate the long-term effectiveness and safety of autologous haematopoiesis stem cell transplantation (AHSCT) for severe, refractory autoimmune diseases in paediatric patients.Methods A single-centre study of consecutive children and adolescents with refractory autoimmune diseases undergoing AHSCT was performed. Demographics, clinical, laboratory features, pre-AHSCT medications, disease activity and functional status were captured. The primary outcome was progression-free survival, secondary outcomes included overall survival, disease-specific treatment responses, disease activity at the last follow-up and AHSCT safety.Results The study included seven patients: two systemic sclerosis, one pansclerotic morphoea, one eosinophilic fasciitis, one juvenile dermatomyositis and two patients with systemic juvenile idiopathic arthritis; four women, three men median age at AHSCT of 10 years (7–19), median follow-up post-AHSCT of 17 years. Median progression-free survival and overall survival was 4.2 years (95% CI: 0.98 to 8.3) and 17 years (95% CI: 11.8 to 22.1), respectively. Progression-free survival rates at 1 and 2 years post-AHSCT were 100% and 77%, respectively. All children survived. All patients are in clinical remission, only four require ongoing immunotherapy. Safety: Three experienced infections, including HHV6, Candida and Ralstonia sepsis; one developed a systemic inflammatory response syndrome; two new onset secondary autoimmune diseases including autoimmune haemolytic anaemia, Graves’ disease and one was found to have a breast fibroadenoma. Treatment toxicity: one cyclophosphamide-associated transient renal failure and pericardial effusion, one patient with amenorrhoea/infertility.Conclusions AHSCT was an effective and safe approach for children and adolescents with treatment-refractory autoimmune diseases. The indication and timing of transplantation requires a careful consideration and a multidisciplinary approach.https://rmdopen.bmj.com/content/10/3/e004381.full |
| spellingShingle | Jasmin Beate Kuemmerle-Deschner Susanne Benseler Joerg C Henes Özlem Satirer Michaela Döring Till Lesk Autologous haematopoiesis stem cell transplantation (AHSCT) for treatment-refractory autoimmune diseases in children RMD Open |
| title | Autologous haematopoiesis stem cell transplantation (AHSCT) for treatment-refractory autoimmune diseases in children |
| title_full | Autologous haematopoiesis stem cell transplantation (AHSCT) for treatment-refractory autoimmune diseases in children |
| title_fullStr | Autologous haematopoiesis stem cell transplantation (AHSCT) for treatment-refractory autoimmune diseases in children |
| title_full_unstemmed | Autologous haematopoiesis stem cell transplantation (AHSCT) for treatment-refractory autoimmune diseases in children |
| title_short | Autologous haematopoiesis stem cell transplantation (AHSCT) for treatment-refractory autoimmune diseases in children |
| title_sort | autologous haematopoiesis stem cell transplantation ahsct for treatment refractory autoimmune diseases in children |
| url | https://rmdopen.bmj.com/content/10/3/e004381.full |
| work_keys_str_mv | AT jasminbeatekuemmerledeschner autologoushaematopoiesisstemcelltransplantationahsctfortreatmentrefractoryautoimmunediseasesinchildren AT susannebenseler autologoushaematopoiesisstemcelltransplantationahsctfortreatmentrefractoryautoimmunediseasesinchildren AT joergchenes autologoushaematopoiesisstemcelltransplantationahsctfortreatmentrefractoryautoimmunediseasesinchildren AT ozlemsatirer autologoushaematopoiesisstemcelltransplantationahsctfortreatmentrefractoryautoimmunediseasesinchildren AT michaeladoring autologoushaematopoiesisstemcelltransplantationahsctfortreatmentrefractoryautoimmunediseasesinchildren AT tilllesk autologoushaematopoiesisstemcelltransplantationahsctfortreatmentrefractoryautoimmunediseasesinchildren |